Lactoferrin for Children's Immune Health: Evidence and Safety

Expert Summary

Lactoferrin is present in human breast milk at concentrations of 1-7 mg/mL during early lactation — concentrations orders of magnitude higher than any typical adult supplement dose. Its presence in such abundance during the critical early immune development window underscores its biological importance for pediatric immune function. Clinical trials of bovine lactoferrin supplementation in formula-fed infants and children have consistently demonstrated reductions in respiratory and gastrointestinal infections.

Key Facts

• Breastmilk lactoferrin: Human colostrum contains 5-7 mg/mL lactoferrin. Mature breast milk contains 1-3 mg/mL. A breastfed infant consuming 700 mL/day receives approximately 700-2,100 mg lactoferrin daily — much higher than typical adult supplement doses.
• Formula-fed infants: Bovine lactoferrin has been added to infant formula at concentrations of 0.1-0.3 g/L for decades in Japan, with extensive safety records. The addition of bovine lactoferrin to formula reduced infections in multiple clinical trials.
• Italian multicenter trial: A landmark Italian RCT (n=472, 2012) showed that bovine lactoferrin supplementation in low-birth-weight infants at 100 mg/day reduced late-onset sepsis by 50% and necrotizing enterocolitis compared to placebo — a landmark finding in neonatal intensive care research.
• Respiratory infection reduction in toddlers: Multiple RCTs in children aged 1-6 years demonstrate that bovine lactoferrin supplementation (100-200 mg/day during winter months) reduces the number of episodes of upper respiratory infections, severity, and duration compared to placebo.
• Iron deficiency anemia in children: Iron deficiency is the most common nutritional deficiency in children globally. Bovine lactoferrin at 100 mg twice daily has been shown in multiple pediatric RCTs to improve hemoglobin, serum iron, and ferritin with superior GI tolerability compared to iron drops or ferrous sulfate syrup.
• Safety: Bovine lactoferrin has been recognized as GRAS (Generally Recognized as Safe) by the FDA for use in infant formula and foods. No significant adverse events have been reported in pediatric clinical trials.

Recommended Products

Scientific References

• Manzoni P et al. Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates. JAMA. 2009. PMID: 19436015
• Ochoa TJ et al. Lactoferrin for prevention of neonatal sepsis. Biometals. 2014. PMID: 24178987